Full Press Release Details
libtayo cemiplimab phase 3 data in the adjuvant treatment of post surgical high risk cutaneous squamous cell carcinoma cscc have potential to be practice changing.
REGN
libtayo cemiplimab phase 3 data in the adjuvant treatment of post surgical high risk cutaneous squamous cell carcinoma cscc have potential to be practice changing
Key Takeaway: libtayo cemiplimab phase 3 data in the adjuvant treatment of post surgical high risk cutaneous squamous cell carcinoma cscc have potential to be practice changing